Tags

Type your tag names separated by a space and hit enter

Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease.
Expert Opin Ther Targets. 2005 Oct; 9(5):923-9.EO

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder with no effective protective treatment, characterised by a massive degeneration of dopaminergic neurons in the substantia nigra and the subsequent loss of their projecting nerve fibres in the striatum. Because current treatments for PD are not effective, considerable research has been focused recently on a number of regulatory molecules that regulate inflammation characteristic of PD, induce neurotrophic and survival factors and reduce oxidative stress. Vasoactive intestinal peptide (VIP), a neuropeptide with a potent anti-inflammatory, antiapoptotic and neurotrophic effect, has been found to be protective in several inflammatory disorders. This review examines the putative protective effect of VIP and analogues in different models for PD. VIP emerges as a potential valuable neuroprotective agent for the treatment of pathological conditions in the CNS, such as PD, in which inflammation-induced neurodegeneration occurs.

Authors+Show Affiliations

Gonzalez-Rey E
Instituto de Parasitologia y Biomedicina, CSIC, Avd. Conocimiento sn, PT Ciencias de la Salud, Granada, Spain.
Chorny A
No affiliation info available
Fernandez-Martin A
No affiliation info available
Varela N
No affiliation info available
Delgado M
No affiliation info available

MeSH

Antiparkinson AgentsHumansParkinson DiseaseVasoactive Intestinal Peptide

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16185148

Citation

Gonzalez-Rey, Elena, et al. "Vasoactive Intestinal Peptide Family as a Therapeutic Target for Parkinson's Disease." Expert Opinion On Therapeutic Targets, vol. 9, no. 5, 2005, pp. 923-9.
Gonzalez-Rey E, Chorny A, Fernandez-Martin A, et al. Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets. 2005;9(5):923-9.
Gonzalez-Rey, E., Chorny, A., Fernandez-Martin, A., Varela, N., & Delgado, M. (2005). Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. Expert Opinion On Therapeutic Targets, 9(5), 923-9.
Gonzalez-Rey E, et al. Vasoactive Intestinal Peptide Family as a Therapeutic Target for Parkinson's Disease. Expert Opin Ther Targets. 2005;9(5):923-9. PubMed PMID: 16185148.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. AU - Gonzalez-Rey,Elena, AU - Chorny,Alejo, AU - Fernandez-Martin,Amelia, AU - Varela,Nieves, AU - Delgado,Mario, PY - 2005/9/28/pubmed PY - 2007/1/26/medline PY - 2005/9/28/entrez SP - 923 EP - 9 JF - Expert opinion on therapeutic targets JO - Expert Opin Ther Targets VL - 9 IS - 5 N2 - Parkinson's disease (PD) is a common neurodegenerative disorder with no effective protective treatment, characterised by a massive degeneration of dopaminergic neurons in the substantia nigra and the subsequent loss of their projecting nerve fibres in the striatum. Because current treatments for PD are not effective, considerable research has been focused recently on a number of regulatory molecules that regulate inflammation characteristic of PD, induce neurotrophic and survival factors and reduce oxidative stress. Vasoactive intestinal peptide (VIP), a neuropeptide with a potent anti-inflammatory, antiapoptotic and neurotrophic effect, has been found to be protective in several inflammatory disorders. This review examines the putative protective effect of VIP and analogues in different models for PD. VIP emerges as a potential valuable neuroprotective agent for the treatment of pathological conditions in the CNS, such as PD, in which inflammation-induced neurodegeneration occurs. SN - 1744-7631 UR - https://www.unboundmedicine.com/medline/citation/16185148/Vasoactive_intestinal_peptide_family_as_a_therapeutic_target_for_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -